Rita Murri1,2, Sara Lardo3, Alessio De Luca4, Brunella Posteraro1,5, Riccardo Torelli1,5, Giulia De Angelis1,5, Francesca Giovannenze1,2, Francesco Taccari1, Lucia Pavan4, Lucia Parroni4, Maurizio Sanguinetti1,5, Massimo Fantoni1,2. 1. Department of Laboratory and Infectious Diseases Sciences, A. Gemelli University Hospital Foundation IRCCS, 00168 Rome, Italy. 2. Infectious Diseases Section, Department of Safety and Bioethics, Catholic University of the Sacred Heart, 00168 Rome, Italy. 3. A. Gemelli University Hospital Foundation IRCCS, 00168 Rome, Italy. 4. Pharmacy Complex Operative Unit, A. Gemelli University Hospital Foundation IRCCS, 00168 Rome, Italy. 5. Department of Basic Biotechnology, Clinical Intensive Care and Perioperative Sciences, Catholic University of the Sacred Heart, 00168 Rome, Italy.
Abstract
Background and Objectives: Overtreatment with antifungal drugs is often observed. Antifungal stewardship (AFS) focuses on optimizing the treatment for invasive fungal diseases. The objective of the present study was to evaluate the utility of a post-prescription audit plus beta-D-glucan (BDG) assessment on reducing echinocandin use in persons with suspected invasive candidiasis. Materials and Methods: This is a prospective, pre-post quasi-experimental study of people starting echinocandins for suspected invasive candidiasis. The intervention of the study included review of each echinocandin prescription and discontinuation of treatment if a very low probability of fungal disease or a negative BDG value were found. Pre-intervention data were compared with the intervention phase. The primary outcome of the study was the duration of echinocandin therapy. Secondary outcomes were length of hospital stay and mortality. Results: Ninety-two echinocandin prescriptions were reviewed, 49 (53.3%) in the pre-intervention phase and 43 (46.7%) in the intervention phase. Discontinuation of antifungal therapy was possible in 21 of the 43 patients in the intervention phase (48.8%). The duration of echinocandin therapy was 7.4 (SD 4.7) in the pre-intervention phase, 4.1 days (SD 2.9) in persons undergoing the intervention, and 8.6 (SD 7.3) in persons in whom the intervention was not feasible (p at ANOVA = 0.016). Length of stay and mortality did not differ between pre-intervention and intervention phases. Conclusions: An intervention based on pre-prescription restriction and post-prescription audit when combined with BDG measurement is effective in optimizing antifungal therapy by significantly reducing excessive treatment duration.
Background and Objectives: Overtreatment with antifungal drugs is often observed. Antifungal stewardship (AFS) focuses on optimizing the treatment for invasive fungal diseases. The objective of the present study was to evaluate the utility of a post-prescription audit plus beta-D-glucan (BDG) assessment on reducing echinocandin use in persons with suspected invasive candidiasis. Materials and Methods: This is a prospective, pre-post quasi-experimental study of people starting echinocandins for suspected invasive candidiasis. The intervention of the study included review of each echinocandin prescription and discontinuation of treatment if a very low probability of fungal disease or a negative BDG value were found. Pre-intervention data were compared with the intervention phase. The primary outcome of the study was the duration of echinocandin therapy. Secondary outcomes were length of hospital stay and mortality. Results: Ninety-two echinocandin prescriptions were reviewed, 49 (53.3%) in the pre-intervention phase and 43 (46.7%) in the intervention phase. Discontinuation of antifungal therapy was possible in 21 of the 43 patients in the intervention phase (48.8%). The duration of echinocandin therapy was 7.4 (SD 4.7) in the pre-intervention phase, 4.1 days (SD 2.9) in persons undergoing the intervention, and 8.6 (SD 7.3) in persons in whom the intervention was not feasible (p at ANOVA = 0.016). Length of stay and mortality did not differ between pre-intervention and intervention phases. Conclusions: An intervention based on pre-prescription restriction and post-prescription audit when combined with BDG measurement is effective in optimizing antifungal therapy by significantly reducing excessive treatment duration.
Authors: Harold C Standiford; Shannon Chan; Megan Tripoli; Elizabeth Weekes; Graeme N Forrest Journal: Infect Control Hosp Epidemiol Date: 2012-04 Impact factor: 3.254
Authors: Matteo Bassetti; Maria Merelli; Elda Righi; Ana Diaz-Martin; Eva Maria Rosello; Roberto Luzzati; Anna Parra; Enrico Maria Trecarichi; Maurizio Sanguinetti; Brunella Posteraro; Jose Garnacho-Montero; Assunta Sartor; Jordi Rello; Mario Tumbarello Journal: J Clin Microbiol Date: 2013-10-09 Impact factor: 5.948
Authors: A L Bienvenu; L Argaud; F Aubrun; J L Fellahi; C Guerin; E Javouhey; V Piriou; T Rimmele; C Chidiac; G Leboucher Journal: J Antimicrob Chemother Date: 2018-02-01 Impact factor: 5.790
Authors: M L Fox; P Barba; I Heras; M López-Parra; M González-Vicent; R de la Cámara; M Batlle; R Parody; C Vallejo; I Ruiz-Camps; L Vázquez Journal: Clin Microbiol Infect Date: 2014-10-13 Impact factor: 8.067